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Exercise induces growth of heart muscle cells and heart size. A new report in Cell (Bostro¨m et al., 2010)
suggests that mice also respond to exercise with increased cardiac myocyte proliferation, and the molecular
regulators of this pathway are linked to maladaptive and pathologic responses to cardiac stresses such as
pressure overload.Shortly after birth, cardiomyocyte prolifer-
ation largely ceases, and continued
growth of the heart is achieved by further
increases in the size of pre-existing cardi-
omyocytes (hypertrophy). Conditions that
place a physiologic gradual increase in
demand on the heart, such as endurance
training or pregnancy, can enhance
cardiac growth rates and pump function
(physiologic hypertrophy). On the other
hand, pathologic stress such as sustained
pressure overload resulting from high
blood pressure or valvular abnormalities,
can lead to a maladaptive form of cardiac
growth (pathologic hypertrophy), which is
associated with loss of cardiomyocytes,
fibrosis, progressive cardiac dysfunction,
and heart failure. At the molecular level,
the similarities and distinctions between
physiologic and pathologic hypertrophy
have remained largely mysterious.
Recently, Bostro¨m and colleagues re-
ported a novel and provocative molecular
relationship between these cellular path-
ways involving CCAAT/enhancer-binding
protein (C/EBP) b, suggesting that one
mechanism by which endurance exercise
enhances cardiac function is by inducing
cardiomyocyte proliferation (Bostro¨m
et al., 2010).
To compare transcriptional programs
regulating pathologic and physiologic
hypertrophy inmice, Bostro¨m et al. utilized
a quantitative PCR-based screening
method, termed ‘‘Quanttrx’’ (Gupta et al.,
2010), and cardiac samples from young
adult mice (12 weeks of age) after thoracic
aortic constriction (TAC) surgery, a model
of pathologic hypertrophy, or swimming
exercise, a model of physiologic hyper-
trophy. They observed little overlap
between the transcriptional programsactivated by these different forms of
stimulation. After further validation, the
authors chose to focus on C/EBPb, which
was dramatically reduced in exercised
hearts (by about 60%), but not in those
exposed to pressure overload.
C/EBPb is a basic-helix-loop-helix tran-
scription factor expressed in a variety of
tissues including fat, liver, and heart. Since
C/EBPb levelswere reducedwith exercise,
Bostro¨m et al. examined heterozygous
mice with partial loss of C/EBPb function.
These animals exhibited signs of endur-
ance training evenwithout exercise. Partial
loss of C/EBPb was associated with an
increase in Cbp/p300-interacting transac-
tivator with ED-rich carboxy-terminal
domain (CITED) 4 expression, and this
increase was necessary for the manifesta-
tion of reduced C/EPb activity. This
suggests that reduced C/EBPb function
and resulting increases in CITED4 are at
least partially responsible for themolecular
consequences of endurance training on
the heart.
Heterozygous C/EBPb mice not only
mimic aspects of exercise-trained ani-
mals, but are also resistant to the malad-
aptive responses normally seen after
exposure to pressure overload. Heterozy-
gous animals show a less steep decline in
cardiac function and fewer signs of heart
failure than wild-type animals after TAC.
Although not examined in this study, it
will be interesting to determine if endur-
ance training provides the same protec-
tion to pathologic stress and if the degree
of protection is enhanced by C/EBPb
haploinsufficiency. Furthermore, it will be
important to confirm that the effects of
C/EBPb haploinsufficiency are due to
loss of function within cardiomyocytesCell Metabolismby analyzing inducible tissue-specific
deletion in adult heart cells.
How is C/EBPb-regulated in response
to exercise, and how does its loss result
in protection from pathologic stress?
The insulin-like growth factor (IGF)
pathway has been implicated in physio-
logic hypertrophy and control of cell size
via activation of thymoma viral proto-
oncogene (AKT) and downstream sig-
naling components (DeBosch et al.,
2006; Dorn and Force, 2005). Bostro¨m
et al. showed that AKT activation results
in downregulation of C/EBPß (Figure 1).
Furthermore, C/EBPb can inhibit binding
of serum response factor (SRF) to DNA,
providing a potential mechanism for regu-
lation of downstream signaling during
hypertrophy. SRF activity in the heart is
potently regulated by the myocardin
family of transcriptional coactivators and
by the homeodomain-containing protein
Hopx. These transcriptional complexes
are implicated in pathologic hypertrophy
downstream of neurohormonal and
calcium-mediated signals (Kook et al.,
2003; Wang et al., 2001). SRF functionally
interacts with other cardiac-specific tran-
scription factors including Nkx2-5 and
Gata4. Loss of C/EBPb as a result of
endurance training might result in
enhanced SRF transcriptional activity
and activation of pathways associated
with pathologic hypertrophy; yet, patho-
logic hypertrophy is reduced in C/EBPb
heterozygotes. Clearly, a more detailed
understanding of the relationship of
C/EBPb to other hypertrophic signaling
cascades is required. In this regard, it is
worth noting that C/EBPb can interact
with nuclear factor of activated T cells
(NFAT) and modulate its activity13, January 5, 2011 ª2011 Elsevier Inc. 3
Figure 1. Signaling Pathways Regulating Physiologic and
Pathologic Cardiac Hypertrophy
Neurohormonal and calcium (Ca2+) -mediated pathways can activate signaling
cascades in cardiac myocytes that lead to activation of maladaptive hyper-
trophy. Exercise, pregnancy, and other physiologic growth stimuli can act
through insulin-like growth factor (IGF) 1 to stimulate phosphoinositide-3
kinase (PI3K) and Akt, which inhibits C/EBPb. C/EBPb may function through
inhibition of CITED4 to regulate physiologic hypertrophy and myocyte prolifer-
ation, and it may also affect the activity of serum response factor (SRF) to
modulate pathologic responses (dotted lines).
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Previews(Oh et al., 2010), and NFAT
can modulate pathologic
hypertrophy downstream of
calcium signaling.
Bostro¨m et al. also noted
a marked increase in DNA
synthesis within cardiomyo-
cytes of endurance-trained
animals. They suggest that
cardiac myocyte proliferation
is enhanced by exercise, and
that myocyte hyperplasia
(more cells) may account for
some of the beneficial effects
of exercise, in addition to
effects mediated by myocyte
hypertrophy.
The ability of adult cardiac
myoctyes to proliferate
remains controversial.
Classic teaching suggests
myocyte proliferation ceases
shortly after birth, but recent
reports indicate that this may
not be the case (Bersell
et al., 2009), and some turn-
over of adult myocytes may
occur in both mice and hu-
mans (Bergmann et al., 2009;
Hsieh et al., 2007). Studies of
cardiomyocyte proliferation
are complicated by the fact
that these cells can be poly-
ploid and undergo DNA
synthesis and nuclear division
to produce multinucleated
cells without undergoingcellular division. DNA synthesis and
polyploidy are increased under conditions
of cardiac stress and hypertrophy, a
response requiring cyclinG1 (Liu et al.,
2010). Thus, the demonstration of DNA
synthesis does not necessarily mean that
more myocytes have been produced.
Bostro¨m et al. addressed this issue by
examining expression of aurora B kinase,
which is a necessary component of the
contractile ring mediating cytoplasmic
separation and cell division. The paper
identifies an increase in aurora B kinase
expressing myocytes after exercise,
although the numbers appear small
(0.2% of myocytes after exercise
compared to >6% of myocytes that had4 Cell Metabolism 13, January 5, 2011 ª2011incorporated BrdU). Hence, it remains
unclear how many myocytes actually
undergo cell division in response to exer-
cise, how many new myocytes are
produced, and to what degree this
accounts for beneficial effects. It will be
of interest to apply alternative quantitative
approaches, such as those used to esti-
mate myocyte turnover after myocardial
infarction or pressure overload (Hsieh
et al., 2007), to validate these findings. It
is also important to determine if similar
changes in myocyte proliferation occur in
older animals, since the mice used in this
study were relatively young (12 weeks
old) and proliferation potential likely
decreases with age.Elsevier Inc.If exercise truly enhances
the heart’s ability to prolif-
erate and regenerate,
perhaps recovery after
myocardial injury would be
enhanced after endurance
training or in C/EBPb hetero-
zygous mice. If so, C/EBPb
may be the tip of a targetable
pathway for cardiac protec-
tion and regeneration in hu-
mans, and future studies
may provide us with yet
more incentive to exercise.
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